Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience reported today that its fiscal third quarter revenues rose 5 percent year over year, driven largely by its newly-acquired Magellan Diagnostics business.

For the three months ended June 30, Meridian posted net revenues of $50.7 million compared to $48.2 million in the year ago quarter, and missing analysts' consensus estimate of $52.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.